{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:G_i",
      "entity_text" : "GI",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03650",
      "entity_text" : "SABR",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "SABR dose escalation reduces biopsy positivity and prostate specific antigen (PSA) nadirs but increases genitourinary (GU) and gastrointestinal (GI) toxicity--no effect on BF has been realized yet.",
  "reading_complete" : "2020-08-04T12:10:49Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:09:01Z",
  "trigger" : "increases",
  "evidence" : [ "SABR dose escalation reduces biopsy positivity and prostate-specific antigen (PSA) nadirs but increases genitourinary (GU) and gastrointestinal (GI" ],
  "pmc_id" : "6043737",
  "score" : 0
}